• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《司美格鲁肽在肾移植后2型糖尿病或移植后糖尿病患者中的安全性和有效性》勘误 [《临床转化内分泌学》36C卷（2024年）100343]

Corrigendum to "Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes" [J. Clin. Translat. Endoc. 36C (2024) 100343].

作者信息

Mohammed Mahzari Moeber, Buraykan Alluhayyan Omar, Hamad Almutairi Mahdi, Abdullah Bayounis Mohammed, Hasan Alrayani Yazeed, Omair Amir A, Saad Alshahrani Awad

机构信息

College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh 22490, Saudi Arabia.

Department of Medicine, King Abdulaziz Medical City, Riyadh, Ministry of National Guard-Health Affairs, Riyadh 14611, Saudi Arabia.

出版信息

J Clin Transl Endocrinol. 2024 Jul 9;38:100360. doi: 10.1016/j.jcte.2024.100360. eCollection 2024 Dec.

DOI:10.1016/j.jcte.2024.100360
PMID:39764278
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11701984/
Abstract

[This corrects the article DOI: 10.1016/j.jcte.2024.100343.].

摘要

[本文更正了文章的数字对象标识符：10.1016/j.jcte.2024.100343。]

相似文献

1
Corrigendum to "Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes" [J. Clin. Translat. Endoc. 36C (2024) 100343].《司美格鲁肽在肾移植后2型糖尿病或移植后糖尿病患者中的安全性和有效性》勘误 [《临床转化内分泌学》36C卷（2024年）100343]
J Clin Transl Endocrinol. 2024 Jul 9;38:100360. doi: 10.1016/j.jcte.2024.100360. eCollection 2024 Dec.
2
Erratum regarding missing Declaration of Competing Interest statements in previously published articles.关于之前发表文章中缺失利益冲突声明的勘误。
J Clin Transl Endocrinol. 2020 Dec 17;23:100242. doi: 10.1016/j.jcte.2020.100242. eCollection 2021 Mar.
3
Erratum regarding missing Declaration of Competing Interest statements in previously published articles.关于已发表文章中缺失利益冲突声明的勘误。
J Clin Transl Endocrinol. 2020 Dec 17;23:100246. doi: 10.1016/j.jcte.2020.100246. eCollection 2021 Mar.
4
Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes.司美格鲁肽在肾移植后2型糖尿病患者或移植后糖尿病患者中的安全性和有效性。
J Clin Transl Endocrinol. 2024 Apr 6;36:100343. doi: 10.1016/j.jcte.2024.100343. eCollection 2024 Jun.
5
Corrigendum to 'Regenerative technologies to bed side: Evolving the regulatory' [J Orthop Translat 9 (2017) 1-7].《再生技术走向临床：监管的演变》[《骨科翻译》9 (2017) 1 - 7]勘误
J Orthop Translat. 2018 Feb 3;12:93. doi: 10.1016/j.jot.2017.12.005. eCollection 2018 Jan.
6
Corrigendum to "Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals" [J. JCTE 2 (2015) 55-60].《关于“在医疗人员监督下，跨性别成年人激素治疗是安全的；对跨性别者激素治疗后遗症的综述”的勘误》[J. JCTE 2 (2015) 55 - 60]
J Clin Transl Endocrinol. 2024 Mar 16;35:100334. doi: 10.1016/j.jcte.2024.100334. eCollection 2024 Mar.
7
Corrigendum to "Gallic acid mediates tumor-suppressive effects on osteosarcoma through the H19-Wnt/β-catenin regulatory axis" [J. Orthop. Translat. (2023) 34-42].《“没食子酸通过H19-Wnt/β-连环蛋白调控轴对骨肉瘤发挥肿瘤抑制作用”的勘误》[《骨科学翻译杂志》(2023年) 第34 - 42页]
J Orthop Translat. 2023 Apr 27;39:194-195. doi: 10.1016/j.jot.2023.04.002. eCollection 2023 Mar.
8
Corrigendum to "Relative frequency of avascular necrosis of the hip as indication for primary Total Hip Arthroplasty in the USA vs. India" [J. Orthop. 36C (2023) 1-6].《美国与印度原发性全髋关节置换术中以髋关节无血管性坏死为指征的相对频率》勘误 [《骨科杂志》36C卷（2023年）第1 - 6页]
J Orthop. 2023 May 5;42:93. doi: 10.1016/j.jor.2023.05.003. eCollection 2023 Aug.
9
Correction to "Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes" 2023; 1(1): 10.1210/jcemcr/luac017).
JCEM Case Rep. 2023 Jan 24;1(1):luad005. doi: 10.1210/jcemcr/luad005. eCollection 2023 Jan.
10
Corrigendum: Safety of Semaglutide.勘误：司美格鲁肽的安全性。
Front Endocrinol (Lausanne). 2021 Nov 10;12:786732. doi: 10.3389/fendo.2021.786732. eCollection 2021.